Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) PT at $80.60

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned a consensus rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $80.60.

A number of research firms have recently commented on PBH. Jefferies Financial Group cut their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Oppenheimer reduced their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $65.88 on Friday. Prestige Consumer Healthcare has a 12 month low of $57.25 and a 12 month high of $90.04. The firm has a market capitalization of $3.12 billion, a P/E ratio of 17.43, a P/E/G ratio of 2.08 and a beta of 0.43. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The business has a fifty day simple moving average of $63.54 and a two-hundred day simple moving average of $63.75.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. During the same period last year, the business earned $1.22 earnings per share. The company’s revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in PBH. Meeder Advisory Services Inc. bought a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $266,000. Heartland Advisors Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 16.5% during the 4th quarter. Heartland Advisors Inc. now owns 74,991 shares of the company’s stock valued at $4,626,000 after buying an additional 10,615 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Prestige Consumer Healthcare by 17.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 4,064 shares of the company’s stock worth $251,000 after buying an additional 618 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Prestige Consumer Healthcare by 5.2% in the fourth quarter. Deutsche Bank AG now owns 40,562 shares of the company’s stock worth $2,502,000 after acquiring an additional 1,998 shares during the period. Finally, Brandes Investment Partners LP increased its position in Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after acquiring an additional 292,744 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).